Pulrodemstat (CC90011)

Description: CC-90011 (LSD1-IN-7) is a novel, highly potent and orally bioavailable inhibitor of lysine specific demethylase-1 (LSD1) with anticancer activity. CC-90011 exhibits potent on-target induction of cellular differentiationin acute myeloid leukemia (AML) and small cell lung cancer (SCLC) celllines, and antitumor efficacy in patient-derived xenograft (PDX) SCLCmodels. CC-90011 is currently in phase 2 trials in patients with firstline, extensive stage SCLC (ClinicalTrials.gov identifier: NCT03850067).

References:

1. Young K. Chen, et al. Compositions comprising an inhibitor of lysine specific demethylase-1. WO2017079670A1.

2. Fang Y, Liao G, Yu B. LSD1/KDM1A inhibitors in clinical trials:advances and prospects. J Hematol Oncol. 2019 Dec 4; 12(1):129. doi:10.1186/s13045-019-0811-9. PMID: 31801559; PMCID: PMC6894138.

3. Fu X, Zhang P, Yu B. Advances toward LSD1 inhibitorsfor cancer therapy. Future Med Chem. 2017 Jul; 9(11):1227-1242. doi:10.4155/fmc-2017-0068. Epub 2017 Jul 19. PMID: 28722477.

4. https://doi.org/10.1021/acs.jmedchem.0c00978

Related CAS #: 2097523-60-7 (besylate) 1821307-10-1 (free base)